
Abbott Laboratories ABT
$ 101.56
1.12%
Annual report 2025
added 02-20-2026
Abbott Laboratories Accounts Receivables 2011-2026 | ABT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.93 B | 6.92 B | 6.56 B | 6.22 B | 6.49 B | 6.41 B | 5.42 B | 5.18 B | 5.25 B | 3.25 B | 3.42 B | 3.59 B | 3.99 B | 7.61 B | 7.68 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.93 B | 3.25 B | 5.73 B |
Quarterly Accounts Receivables Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.97 B | 7.33 B | 7.05 B | 6.85 B | 6.6 B | 6.5 B | 6.17 B | 6.02 B | 6.22 B | 6.41 B | - | 7.18 B | 6.49 B | 6.4 B | 6.11 B | 6.1 B | 6.41 B | 6.41 B | 6.41 B | 6.41 B | 5.42 B | 5.42 B | 5.42 B | 5.42 B | 5.18 B | 5.18 B | 5.18 B | 5.18 B | 5.25 B | 5.25 B | 5.25 B | 5.25 B | 3.25 B | 3.25 B | 3.25 B | 3.25 B | 3.42 B | 3.42 B | 3.42 B | 3.42 B | 3.59 B | 3.59 B | 3.59 B | 3.59 B | 3.99 B | 3.99 B | 3.99 B | 3.99 B | 7.61 B | 7.61 B | 7.61 B | 7.61 B | 7.68 B | 7.68 B | 7.68 B | 7.68 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.97 B | 3.25 B | 5.58 B |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
996 M | - | - | $ 14 B | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 12.65 | - | $ 1.71 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Bio-Rad Laboratories
BIO
|
452 M | $ 295.96 | 1.28 % | $ 8.35 B | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | - | - | $ 132 M | ||
|
Bruker Corporation
BRKR
|
566 M | - | - | $ 5.88 K | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.59 | 0.37 % | $ 36.7 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 1.94 | -2.02 % | $ 1.18 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 10.46 | 0.77 % | $ 296 M | ||
|
Inogen
INGN
|
38.9 M | $ 6.2 | -2.21 % | $ 165 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.04 | 0.97 % | $ 17.6 M | ||
|
Electromed
ELMD
|
24.7 M | $ 25.71 | 1.98 % | $ 217 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 6.25 | 3.48 % | $ 74.7 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
679 M | $ 94.55 | -0.41 % | $ 12.8 B | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 17.85 | -0.06 % | $ 419 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 4.86 | 9.46 % | $ 1.03 B | ||
|
Myomo
MYO
|
4.1 M | $ 0.8 | 1.01 % | $ 33.5 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 10.99 | 1.01 % | $ 394 M | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 56.64 | -0.33 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
248 M | $ 39.44 | -0.73 % | $ 1.22 B | ||
|
LivaNova PLC
LIVN
|
216 M | $ 65.14 | 0.23 % | $ 3.55 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 87.94 | -0.78 % | $ 3.05 B | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
660 M | $ 78.2 | - | $ 45.7 B | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.74 | -2.14 % | $ 7.6 M |